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Abstract
Background: Pancreatic cancer is an extremely aggressive malignancy. Subjects are afflicted with
a variety of disconcerting symptoms, including profound cachexia. Recent data indicate that the
outcome of oncological patients suffering from cancer cachexia could be improved by parenteral
nutrition and that parenteral nutrition results in an improvement of quality of life and in prolonged
survival.
Currently, there is no recommendation of routine use of parenteral nutrition. Furthermore, there
is no clear recommendation for 2nd line therapy (or higher) for pancreatic adenocarcinoma but
often asked for.
Methods/Design: PANUSCO is an open label, controlled, prospective, randomized, multicentre
phase IIIb trial with two parallel arms. All patients will be treated with 5-fluorouracil, folinic acid
and oxaliplatin on an outpatient basis at the study sites. Additionally, all patients will receive best
supportive nutritional care (BSNC). In the experimental group BSNC will be expanded with
parenteral nutrition (PN). In contrast, patients in the control group obtain solely BSNC. Parenteral
nutrition will be applied overnight and at home by experienced medical staff.
A total of 120 patients are planned to be enrolled. Primary endpoint is the comparison of the
treatment groups with respect to event-free survival (EFS), defined as the time from randomization
till time to development of an event defined as either an impairment (change from baseline of at
least ten points in EORTC QLQ-C30, functional domain total score) or withdrawal due to fulfilling
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the special defined stopping criteria for chemotherapy as well as for nutritional intervention (NI)
or death from any cause (whichever occurs first).
Discussion: The aim of this clinical trial is to evaluate whether parenteral nutrition in combination
with defined 2nd line or higher chemotherapy has an impact on quality of life for patients suffering
from pancreatic adenocarcinoma.
Trial registration: Current Controlled Trials ISRCTN60516908.
Background
Pancreatic cancer is an extremely aggressive malignancy
characterized by extensive invasion, early metastasis, and
marked cachexia. The yearly incidence of pancreatic can-
cer overlaps the mortality rate and the 5-year survival rate
is less than 5% [1]. Subjects are afflicted with a variety of
disconcerting symptoms, including profound cachexia
and deterioration in performance status (PS), even when
their tumour burden is low [2,3]. Therefore, one of the
most important therapeutic targets is the improvement of
quality of life (QoL) [4].
Cachexia is a strong independent predictor of mortality,
poor therapeutic response, diminished functional capac-
ity, and reduced QoL. It is defined as the debilitating state
of involuntary weight loss, often connected with anorexia,
tissue wasting, malnutrition, and inability for natural
nutrition intake. The combination of these symptoms is
also named "cancer anorexia-cachexia syndrome" [4]. The
most important phenotypic feature is muscle wasting and
functional impairment as a result of increased protein
degradation and reduced protein synthesis or both [5]. In
addition, it is a life-threatening and debilitating syndrome
for 50% of all cancer subjects [5]. Compared to other solid
tumours, the pancreatic cancer has the highest incidence
for cancer cachexia (CC), as much as 80% at the time of
diagnosis [4].
It has to be considered that the full effect of CC can not be
identified by weight loss alone. Reduced food intake and
systemic inflammation are also involved. Therefore, a
multifactor cachexia profile was developed by the group
of Bauer et al., based on weight loss, food intake and
inflammatory status. These variables were investigated by
determination of dietary intake, body composition, nutri-
tional status, functional capacity and QoL in subjects with
CC receiving chemotherapy [6].
As reported, the QoL is significantly impaired in CC sub-
jects and there is evidence for increased morbidity and
mortality of subjects with CC [5]. Subjects suffering from
CC commonly have derangements in basal metabolic rate
as well as reduced appetite and food intake. Even moder-
ate weight loss is associated with psychological stress and
lower QoL. Furthermore, CC affects subject's surgical risk
and response to first- and second-line chemo-/radiother-
apy [5]. Cachectic subjects are difficult to guide through
chemotherapy experiencing more severe side effects
resulting in progressive cachexia. The outcomes of sub-
jects with CC receiving chemotherapy can be improved
parenteral nutrition (PN) [6]. Supplementation with PN
improves the QoL in subjects with advanced CC [7]. There
are also data indicating that PN has a synergistic effect
with chemotherapy and results in better clinical outcome
[6,7]. Further research in form of randomized controlled
trials is required to confirm these results. Besides, it is
important to establish criteria for starting PN in cancer
subjects [8]. The European Society of Parenteral and
Enteral Nutrition (ESPEN) recommend PN only for mal-
nourished subjects but does not reflect situation in CC
patients. Furthermore, there is no recommendation of
routine use of PN during chemotherapy, radiotherapy or
a combined therapy [5,9].
At present, no 2nd line therapy (or higher) is recom-
mended for pancreatic adenocarcinoma, but often asked
for [10]. In this clinical trial 5-FU (5-fluorouracil), folinic
acid (FA) and oxaliplatin will be given as chemotherapy
according to the OFF-scheme developed in the context of
the clinical trial CONKO-003 [11]. This trial proofed a
clinical benefit of 5-FU plus oxaliplatin as 2nd line chem-
otherapy for subjects suffering from pancreatic adenocar-
cinoma. The reported median Overall Survival (OS) of 5
months is significantly higher than in the control group
receiving 5-FU and FA (4.1 month; p = 0.014). Data from
literature report median OS ranging from 4.3 month to
6.5 month [12,13]. Nevertheless, more scientific work is
required to show that 2nd line chemotherapy especially in
combination with PN can improve the QoL in subjects
suffering from pancreatic cancer.
Methods/Design
Trial organization
PANUSCO is designed and coordinated by the Depart-
ment of Surgery, University of Heidelberg and the
National Center for Tumor Diseases (NCT) in Heidelberg.
Heidelberg is responsible for overall trial management,
regulatory affairs, statistical planning and analysis, trial
registration (International Standard Randomised Con-
trolled Trial Number (ISRCTN60516908), http://BMC Cancer 2009, 9:412 http://www.biomedcentral.com/1471-2407/9/412
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www.controlled-trials.com) and reporting as well as qual-
ity assurance. The responsibility for external monitoring
and pharmacovigilance is carried forward to independent
Contract Research Organisations (CRO). The trial will be
performed at four University Hospitals in Germany. The
trial is sponsored by the foundation "Leben mit Krebs" in
Germany. The financial sponsor is not involved in the
data base management and has no access to the randomi-
sation code.
Investigators
Patients will be recruited by the four planned study sites.
Special contracts will be disposed with the involved study
centres. Due to the multimodal nature of the trial, all
investigators will either be experienced oncologists or gas-
troenterologists. Additional, for the NI experienced nutri-
tionists will take care for PN and BSNC.
Data Safety Monitoring Board
An independent Data Safety Monitoring Board (DSMB)
consisting of three experts (one expert in pancreatic carci-
noma, one expert in nutritional medicine and one expert
in biostatistics) will evaluate the clinical research data on
an ongoing basis to assure patient safety and study integ-
rity for the clinical trail. The board will monitor the trial
data, in particular the safety data, and makes recommen-
dations based on the periodically reviewed data. Respon-
sibilities are laid down in a DSMB Charta.
Medication supply
All chemotherapeutic agents will be prepared and pro-
vided by the corresponding pharmacy. Chemotherapeutic
medication will be prepared for each patient specifically
and delivered just prior to administration to the outpa-
tient's department. PN will be applied overnight at
patient's home by medical-experienced staff. Therefore,
PN will be prepared at pharmacies next to the patient's
home.
On-site monitoring
Monitoring will be done by personal visits from clinical
monitors according to the Standard Operating Procedures
(SOPs) of the independent, external CRO. Monitors will
review the entries into CRFs on the basis of source docu-
ments (30% source data verification). Data management
will be performed by the Institute of Medical Biometry
and Informatics (IMBI) at the University of Heidelberg.
Pharmacovigilance is outsourced to a further CRO special-
ized on safety issues. Both data bases will be aligned at the
end of the trial.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Medical School at Sep-
tember 22nd, 2009. The clinical trial complies with the
Helsinki Declaration from 2008, the Medical Associa-
tion's professional code of conduct, the principles of
Good Clinical Practice (GCP) guidelines and the Federal
Data Protection Act. The trial will also be performed in
keeping with local legal and regulatory requirements. The
medical secrecy and the Federal Data Protection Art will
be followed.
Written informed consent for the clinical trial PANUSCO
and respectively separate informed consent for the accom-
panying translational research will be obtained from each
participating patient in oral and written from before
inclusion in the trial. The nature, scope and possible con-
sequences of the trial have been explained by a physician
in detail. The investigator will not undertake any meas-
ures for the clinical trial or the translational research until
valid consent has been obtained.
Patient selection
PANUSCO focuses on hospitalised patients over 18 years
of age suffering from advanced pancreatic adenocarci-
noma with previous progression under chemotherapy.
Men and women over 18 years with histological con-
firmed advanced pancreatic adenocarcinoma which have
received at least one previous chemotherapy (gemcitab-
ine-based) will be screened for participation in the clinical
trial. Patients will be contacted first-time by the (sub-)
investigators at the outpatient's department. A detailed
overview of recruitment criteria for inclusion and exclu-
sion is given in table 1.
Study design
PANUSCO is an open label, controlled, prospective, ran-
domized, multicentre phase IIIb trial with two parallel
study arms (Figure 1). All Patients receive chemotherapy
(a combination of 5-flourouracil (5-FU), folinic acid (FA)
and oxaliplatin) at an outpatient's basis at the study sites.
Additional, the patients in experimental group receive
BSNC expanded with PN containing a total of 1150 kcal
for each application. PN will be given by medical-experi-
enced staff overnight at patients home. The control group
receives solely BSNC consisting of nutritional advice.
Every kind of enteral nutrition and oral supplementation
is allowed for patients in both study arms.
Study objectives
Primary objective is the comparison of the treatment
groups with respect to event-free survival (EFS). EFS is
defined as the time from randomization till time to devel-
opment of an event defined as either an impairment
(change from baseline of at least ten points in EORTC
QLQ-C30, functional domain total score) or withdrawal
due to fulfilling the special defined stopping criteria for
chemotherapy as well as PN and Best Supportive Nutri-BMC Cancer 2009, 9:412 http://www.biomedcentral.com/1471-2407/9/412
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tional Care (BSNC) in Arm A or BSNC alone in Arm B or
death from any cause (whichever occurs first). Chemo-
therapy will be continued until individual stop-criteria
(disease progression, unacceptable toxicity) are met. This
is unaffected by the (dis-) continuation of NI in both
study arms. NI in both arms will be stopped when two of
the three following criteria are met:
1. weight loss > 2% within the last seven days or
caloric intake ≤ 500 kcal expected within the next five
days,
2. BIA (Bioimpedance Analysis) defined by phase
angle and body cell mass (BCM) with a deterioration
> 10% (in both parameters)
3. Prognostic Inflammatory and Nutritional Index
(PINI) > 10 (only in subjects with no sign of acute
inflammation).
This is unaffected by the (dis-) continuation of chemo-
therapy.
Secondary objectives are the comparison of the treatment
groups with respect to tumour-cachexia, Objective
Response Rate (ORR), Time to Progression (TTP), Progres-
sion Free Survival (PFS), Overall Survival (OS), Toxicity,
time from randomization till time point when stopping
criteria are met. Furthermore, the definition and evalua-
tion of a scoring system identifying subject groups who
will benefit from second line chemotherapy and/or PN.
Accompanying translational research is focussing mainly
on molecular signalling as well as on inflammatory
Table 1: Eligibility Criteria
Inclusion criteria Exclusion criteria
Written informed consent (IC) Major surgery < 4 weeks prior to enrolment
Histological confirmed advanced pancreatic adenocarcinoma Weight loss > 2% within the last seven days or caloric intake ≤ 500 kcal 
expected within the next five days
At least one previous chemotherapy (gemcitabine-based) PINI-Index > 10
≥ 18 years old Pregnancy or breastfeeding
Body weight ≥ 50 and ≤ 95 kg > 4 weeks of parenteral nutrition within the last 6 months
BMI ≥ 19 Parenteral nutrition < 4 weeks prior to enrolment
Negative pregnancy test (females of childbearing potential) Vulnerable populations (e. g. subjects incapable of giving consent personally)
Willingness to perform double-barrier contraception during study Subject selection conflicts with warnings, precautions and contraindications 
stated for any investigational product
Expected life expectancy > 3 months
Figure 1
 BMC Cancer 2009, 9:412 http://www.biomedcentral.com/1471-2407/9/412
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parameters. The available results will be correlated with
the clinical parameters.
Randomisation and standardised treatment scheme
All patients enrolled will be identifiable throughout the
study. The investigator will maintain a personal list of
patient numbers and patient names to enable records to
be found at a later date. Upon inclusion each patient
receives a unique identification number. After the
patient's eligibility for randomisation has been assessed
he/she will be randomly assigned to one of the two treat-
ment arms (1:1) and receives a unique randomization
number. The randomisation will be done and docu-
mented centrally and send by fax. Stratification will be
performed prior to randomization by Eastern Cooperative
Oncology Group Performance Status (ECOG PS) (stratum
1: PS < 2, stratum 2: PS ≥ 2). The randomisation list will
be kept in safe and confidential custody at the involved
CRO. The method of randomisation and the block sizes
themselves will not be disclosed to the study sites, the
monitors or any person involved in the clinical trial con-
duct. This information will be kept with the randomisa-
tion list.
Treatment scheme
After implantation of a catheter patients will be treated as
follows:
Both study arms receive a chemotherapy consisting of
2000 mg/m2/day 5-FU by IV (24 hours) 200 mg/m2/day
FA IV (30 min) on day 1, 8, 15 and 22 together with 85
mg/m2/day oxaliplatin IV (2 hour) on day 8 and 22. Ther-
apy will be interrupted between days 23 to 42. This cycle
will be repeated until any stop-criterion for chemotherapy
(disease progression or unacceptable toxicity) is met.
Furthermore, all patients receive nutritional consultation
and recommendation by experienced nutritionist con-
templated as BSNC.
Experimental group
Additionally, patients in experimental group receive a
total amount of 1036 ml PN, applied over night via port
system. The PN will be administered continuously six
days a week. An interruption will be performed during
chemotherapy. Beyond, an adjournment of the PN up to
two days is possible; an adjournment of three days is only
once possible during participation of the clinical trial.
Evaluation, toxicity-based dose adjustment and follow-up
All patients must have appropriate lab and radiographic
studies conducted prior to study enrolment to meet eligi-
bility criteria. Lab parameters will be obtained at least
weekly and imaging will be performed every seven weeks.
The patient will be asked at each visit for any adverse event
(AE) as well as concomitant medication and pain medica-
tion. Quality of life (QoL) questionnaires (QLQ-C30 and
the pancreas specific PAN 26 questionnaire) will be
handed out to all patients on day 1 and day 22 of each
cycle prior to chemotherapy. Decisions regarding weekly
chemotherapy treatment and chemotherapy dose-adjust-
ment will be made using the guidelines below and based
on haematological parameters monitored once weekly
during chemotherapy. In case of grade 3 or grade 4 hae-
matological toxicities chemotherapy should be held until
resolution or until toxicity has resolved or dropped to
grade 2. PN will be continued. The procedures for patients
with leukocytes between 1.0/l and 1.5/l will be discussed
individually in the study group. In case of grade 3 or grade
4 gastrointestinal toxicities (including anorexia, dehydra-
tion, nausea/vomiting, diarrhoea, mucositis and bleed-
ing) patients will be considered for periodic outpatient
intravenous rehydration with anti-emetics according to
conventional practice guidelines. Any grade ≥ 2 neurotox-
icity should lead to discontinuation of chemotherapy
until recovery to at least grade 1. All uncertain cases of tox-
icities will be discussed by the study group discretion.
Patients can withdraw from study participation at any
time. Patients are taken off the study if unacceptable tox-
icity appears. Unacceptable toxicity is defined as serious
side effect or irreversible grade 4 toxicity, independent
whether they are expected or unexpected. After the indi-
vidual ending of the study subjects will receive the best
available medical and nutritional care. Patients will
undergo imaging and lab analysis (including tumor
marker) quarterly and will be tracked by quarterly phone
follow-up until death.
Statistical consideration and sample size estimation
Three analysis sets are defined: the Intent-to-Treat (ITT)
population including all patients who are randomized
with study medication assignment designated according
to initial randomization, regardless of whether patients
receive study medication or receive a different medication
from that to which they were randomized. This will be the
primary population for evaluating all efficacy endpoints
as well as subject characteristics.
The safety population consisting of all patients who
received at least one dose of study medication. The per
protocol population, consisting of all patients of the ITT
population who completed at least one chemotherapy
cycle, have at least 2 post-baseline assessments regarding
the primary endpoint without pre-specified, selected
major protocol deviations thought to impact on efficacy
analysis.BMC Cancer 2009, 9:412 http://www.biomedcentral.com/1471-2407/9/412
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Primary analysis
Stratification of patients regarding performance status
prior to randomization may improve the power of the
trial. For this reason the main analysis will be stratified by
ECOG (stratum 1: PS < 2, stratum 2: PS ≥ 2) using the ITT
population. A stratified log rank test will be used to com-
pare the two treatment arms regarding the primary varia-
ble. The EFS-rates will be derived from the Kaplan Meier
estimate and the confidence intervals will be calculated
using Greenwood's formula. The above method relies on
the assumption that events are recorded at the time they
occur and there is no lag in the time at which they are
reported. If this assumption is not satisfied, an alternative,
interval censored analysis will be used.
Secondary analyses
A sensitivity analysis will be performed on the primary
variable to assess the impact of protocol deviations using
the per protocol analysis set.
The hazard ratio and the related 95% confidence interval
(CI) for the experimental arm relative to control arm will
be estimated by proportional hazard regression with treat-
ment, centre and performance status as covariates.
OS, PFS, and TTP will be analyzed in the same manner as
in the primary efficacy endpoint. Estimates of the ORR
and 95% CI will be calculated and will be compared
between treatment groups using the Cochran-Mantel-
Haenszel (CMH) test adjusting by the stratification varia-
bles used in the stratified log rank test. For subjects with
incomplete follow-up, time to last follow-up date will be
used as the censoring time in the analysis of time-to-event
data.
Descriptive statistics will be provided for the tumour-
cachexia parameters. QoL scales, subscales and single item
scores will be summarized by the mean and median for
each arm and plotted by time. QoL data will be analysed
using ANCOVA techniques. A logistic regression analysis
will be carried out to identify relevant prognostic factors.
Incidence rates and 95% CI of Adverse Events (AEs) will
be summarized. Subject disposition will be tabulated.
Baseline characteristics, concomitant medications, vital
signs and PS will be tabulated. Study drug administration
and reasons for the deviations from the planned therapy
will be tabulated. Summary tables will be prepared to
examine the distribution of laboratory measures over
time.
Interim analysis
One interim analysis is to be conducted when approxi-
mately 50% of the events have occurred. The nominal
one-sided significance levels for the interim analysis are
0.0026 and 0.0240, respectively.
The objectives of the interim analyses are early stopping of
the trial in case of extreme differences in the event rates
while maintaining the overall two-sided significance level
for the final analysis at 0.05 and assessing safety, includ-
ing any unexpected toxicity.
All statistical tests will be performed at a two-sided signif-
icance level of 0.05 apart from the nominal one-sided sig-
nificance levels of the interim analysis and final analysis
determined by using the O'Brien-Fleming stopping rule.
Sample size estimation
The sample size is calculated to detect differences in the 4-
month EFS-rates and is based on a comparison of two
groups using the unstratified log rank test. The 4-month
EFS-rates are assumed to be 60% and 40% (HR = 0.557)
in the experimental and control group, respectively based
on data from literature [6,7]. Applying one interim analy-
sis according to group sequential design with two stages
using the O'Brien and Fleming type, a 1:1 randomization,
and assuming an accrual time of 36 and a follow-up time
of 4 months a total of 102 patients and of 93 events are
required for a two-sided log rank test with an overall two-
sided significance level of 0.05 and power of 0.80 With
the expectation that approximately 15% of patients may
be lost to follow up, it is estimated that 120 patients will
need to be enrolled. Formula of Schoenfeld [14] used for
the calculation of the number of events. The ADDPLAN,
Version 4.0 calculator was used for the sample size estima-
tion. Stratification of heterogeneous patients regarding
performance status prior to randomization may improve
the power of the trial. We expect an additional stratifica-
tion effect and in case of a smaller than the assumed true
treatment effect the lost of power will be decreased. The
primary analysis will be therefore performed with the
stratified log rank test.
The statistical analysis will be carried out by the responsi-
ble biostatistician at the National Center for Tumor dis-
eases (NCT) Heidelberg. The analysis will be done as soon
as the database has been declared to be complete and
accurate and has been locked. The details of the analysis
will be laid out in the statistical analysis plan, which will
be finalized and approved prior to the database lock. It
has to be authorized before by the biometrician, the spon-
sor, and the Coordinating Investigator.
Discussion
As outlined in the background section patients with
advanced pancreatic carcinoma have to deal with several
problems: (1) their life-expectancy is short; (2) they suffer
from cachexia and deterioration in performance statusBMC Cancer 2009, 9:412 http://www.biomedcentral.com/1471-2407/9/412
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[4]; (3) cachexia is a strong independent predictor of mor-
tality, poor therapeutic response, diminished functional
capacity, and reduced QoL; (4) pancreatic cancer has the
highest incidence for cancer cachexia (CC), as much as
80% at the time of diagnosis [4], (5) cachectic patients are
difficult to guide through chemotherapy experiencing
more severe side effects resulting in progressive cachexia.
There are data indicating that the outcomes of subjects
with CC receiving chemotherapy can be improved with
PN [6]. Supplementation with PN improves the QoL in
subjects with advanced CC [7]. There are also data indicat-
ing that PN has a synergistic effect with chemotherapy and
results in better clinical outcome [6,7].
Unfortunately, most to nearly all clinical trials dealing
with nutritional intervention enrol either patients with
different tumours, and/or undefined oncological treat-
ment and/or treat them with not precisely defined nutri-
tion recorded often retrospective by the subjects in diaries.
It is our aim to perform with PANUSCO a clinical trial
which allows investigating as exactly as possible the
impact of PN in cancer patients. To make the groups com-
parable we restrict the trial to subjects with histological
confirmed pancreatic carcinoma, treat them with defined
chemotherapy and randomize them to defined PN and
BSNC or solely BSNC. As patients often do not stick to
restrictions and/or instructions for oral intake we decided
to allow every kind of oral or enteral supplementation
and use PN to be sure about compliance in the experimen-
tal group.
Conclusion
PANUSCO offers to our knowledge for the first time the
chance to investigate the importance of NI in cancer
cachexia in a clear defined setting. This might have impli-
cations for other entities and for supportive therapy ion
oncology.
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